Tildrakizumab for Prevention of Acute Graft-Versus-Host Disease
Status:
Recruiting
Trial end date:
2025-01-01
Target enrollment:
Participant gender:
Summary
This is a phase 2 open-label trial designed to evaluate the efficacy of tildrakizumab in
improving graft-versus-host disease (GVHD)-free relapse-free survival after myeloablative
allogeneic hematopoietic cell transplantation (alloHCT) for hematologic malignancy.